SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03344809

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

ENABLE-NGS: Enhancing Diagnosis in Chronic B-cell Lymphoproliferative Disorders Using Next-Generation Sequencing

To enhance the diagnosis of unclassifiable, non-CLL B-LPDs using next-generation sequencing technology.

NCT03344809 Lymphoma
MeSH: Lymphoproliferative Disorders
HPO: Lymphoproliferative disorder


Primary Outcomes

Description: This will be reported as a percentage of the total number of cases sequenced

Measure: Proportion of cases where a definite category and/or detectable mutation can be identified.

Time: 2 years

Secondary Outcomes

Description: Age and sex distribution will be reported along with the proportion of cases in each immunomorphologic category

Measure: Demographics and distribution in each immunomorphological category

Time: 2 years

Description: The distribution of mutations within each immunomorphological category will be reported descriptively.

Measure: Correlation of each immunomorphological category with the mutation profile.

Time: 2 years

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 V600E

While some of these mutations, such as the BRAF V600E mutation in Hairy Cell Leukaemia (HCL)2, are now accepted as disease defining mutations, others such as MYD88 and NOTCH1/2 mutations are found in more than one subtype of B-LPD3. --- V600E ---



HPO Nodes


HPO:
Lymphoproliferative disorder
Genes 8
KRAS MYD88 IL2RG CD70 CD27 MCM4 NRAS ZAP70